Aldeyra Therapeutics, Inc.

4.27 USD
+0.05 (+1.18%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aldeyra Therapeutics, Inc. stock is up 33.86% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 March’s closed higher than February. In the last 2 Unusual Options Trades, there were 2 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Feb 15:42 15 Mar, 2024 2.50 CALL 1000 257
28 Feb 20:22 17 Jan, 2025 7.50 CALL 999 110

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.